Therapeutic Advances and Evolving Treatment Strategies: Novel Approaches to Migraine Management

Please Log In or Register to continue.

Release Date: July 10, 2017
Expiration Date: July 10, 2018

Expected time to complete this activity as designed: 60 minutes

There are no fees for participating in or receiving credit for this online activity.

Program Overview

Exciting clinical trials are underway which show great promise in narrowing the unmet clinical need in the preventive treatment of migraine. Data suggest that calcitonin gene-related peptide (CGRP) inhibitors are going to usher in a new era in treatment. How will these novel agents affect your practice?

Our nationally renowned faculty present the most up-to-date information and data being reported in clinical trials for the new CGRP inhibitors. Whether you’re learning this information for the first time or you want to hear the newest information about how CGRP inhibitors will change your practice, this program will provide you with new insight into how what’s happening in clinical trials today will impact your practice in the near future.

This enduring program was streamed live from the 59th Annual Scientific Meeting - American Headache Society.

Target Audience

This activity is designed for neurologists, primary care clinicians, nurses, and pharmacists specializing in headache management.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Correlate current challenges and unmet needs in migraine prevention with the clinical impact on patients
  • Describe the mechanism of action of CGRP, relating how CGRP-based therapies will impact the pathophysiologic development of migraine
  • Summarize data focusing on emerging novel agents for preventive treatments associated with episodic and chronic migraine

Agenda

The Migraine Evolution Process and Treatment Today – Alan M. Rapoport, MD

The Science of Migraine – Stewart J. Tepper, MD

From Bench to Practice: Expert Perspectives on Emerging Strategies and Novel Agents for Migraine Prevention – David W. Dodick, MD - Chair

Looking Toward the Future: Panel Discussion

Instructions for Participation and Credit

This activity is eligible for credit through July 10, 2018. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME and CNE may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biographies

David W. Dodick, MD – Chair
Professor of Neurology
Department of Neurology
Mayo Clinic
Phoenix, Arizona

Dr. David Dodick is a Professor of Neurology at the Mayo Clinic College of Medicine and a consultant in neurology at the Mayo Clinic in Scottsdale, Arizona, as well as the Past-President of the American Headache Society. He is the Program Director of the Mayo Clinic Neurology Residency Program and Headache Medicine Fellowship Program, and the Director of the Headache Program and the Sports Neurology and Concussion Program at Mayo Clinic in Arizona.

In addition, Dr. Dodick is an Adjunct Professor and International Chair of Headache in the Department of Neurosciences, Norwegian University of Science and Technology. Dr. Dodick is also President of the International Headache Society, Chair of the American Migraine Foundation.

Alan M. Rapoport, MD
Clinical Professor of Neurology
David Geffen School of Medicine at UCLA
Los Angeles, California

Dr. Alan Rapoport is a Clinical Professor of Neurology at the David Geffen School of Medicine at UCLA, Los Angeles, California, where he teaches medical students, neurology residents, and fellows. He is the co-founder of BonTriage, an IT company in Silicon Valley, California, dedicated to helping patients and doctors around the globe by collecting detailed patient histories online and linking with an app that monitors patient progress and outcomes. The company has started with headache and is moving into sleep, depression, anxiety, chronic pain, and other areas.

Dr. Rapoport is board certified in neurology and headache medicine. He is immediate past president of the International Headache Society (IHS) and the Fairfield County Neurological Society (Connecticut). He is founder and director-emeritus of The New England Center for Headache in Stamford, Connecticut, founding president of the Headache Cooperative of New England (HCNE), founding director of the Headache Cooperative of the Pacific (HCOP), and was the chairman of the Education and Membership Committee of the IHS. In addition, Dr. Rapoport has served on the Board of Directors of the American Headache Society (AHS) and is currently a member of the board of trustees of the IHS. He is an editor of Headache, CNS Drugs, and editor-in-chief of Neurology Reviews. In addition, he reviews for many peer-reviewed journals including Cephalalgia, Neurology, New England Journal of Medicine, and Headache. Dr. Rapoport has co-authored nine books on headache for patients, physicians and nurses, and more than 300 articles, chapters, and posters on headache and other neurological diseases. He has lectured around the country and internationally to general physicians and headache specialists on all aspects of headache pathophysiology, diagnosis and treatment, and has appeared many times on national radio and television programs including Today and Good Morning America.

Stewart J. Tepper, MD
Professor of Neurology
Geisel School of Medicine at Dartmouth
Hanover, New Hampshire

Dr. Stewart Tepper received his medical degree from Cornell University Medical College. He completed his internal medicine internship at Boston University Hospital, his PGY-2 internal medicine residency at University of Washington School of Medicine, and his neurology residency at Harvard. Dr. Tepper is Professor of Neurology at the Geisel School of Medicine at Dartmouth (Dartmouth Medical School), Hanover, New Hampshire, and Director of the Dartmouth Headache Center, Department of Neurology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.

Dr. Tepper is board-certified in headache medicine. He is co-director of the Scottsdale Headache Symposium course of the American Headache Society, and was also director of the Headache Therapy course for the American Academy of Neurology. He is editor-in-chief of the journal Headache Currents, and associate editor for Headache. Dr. Tepper has published more than 320 peer-reviewed manuscripts, editorials, and books, including The Cleveland Clinic Manual of Headache Therapy, Second Edition.

Accreditation

MediCom CME CREDIT
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ACPE CPE CREDIT
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-17-159-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
MediCom NURSING CREDIT
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 17-159-059

Disclosure

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosures

Dr. David Dodick has received honoraria as a consultant from Acorda, Alder BioPharmaceuticals Inc., Allergan, Inc., Amgen Inc., Autonomic Technologies, Inc., Boston Scientific Corporation, CoLucid Pharmaceuticals Inc., Dr. Reddy’s Laboratories Ltd., Eli Lilly and Company, eNeura Inc., GBS Ventures, Insys Therapeutics, Inc., Merck & Co., Inc., Promius Pharma, LLC., TEVA Pharmaceutical LTD, Tonix Pharmaceuticals Holding Corp., Trigemina, Inc., Xenon Pharmaceuticals Inc., and Zosano Pharma Corporation. He has received royalties from Cambridge University Press and Oxford University Press. He has stock options with EPIEN Medical, Inc., GBS/Nocira, and Mobile Health, and has a consulting use agreement with NAS.

Dr. Alan Rapoport has received honoraria as a consultant from Acorda, Autonomic Technologies, Inc., Avanir Pharmaceuticals, Inc., Depomed, Inc., Dr. Reddy’s Laboratories Ltd., electroCore, LLC, Impax Laboratories, Inc., PERNIX Therapeutics, TEVA Pharmaceutical LTD, and Zosano Pharma Corporation, as well as honoraria related to speakers’ bureau activities from Avanir and Depomed.

Dr. Stewart Tepper has received honoraria as a consultant from Acorda, Alder BioPharmaceuticals Inc., Allergan, Inc., Amgen Inc., ATI, Avanir Pharmaceuticals, Inc., BioVision Inc., electroCore, LLC, Eli Lilly and Company, eNeura Inc., Kimberly-Clark, PERNIX Therapeutics, Pfizer Inc., TEVA Pharmaceutical LTD, and Zosano Pharma Corporation; and honoraria related to formal advisory activities from Alder, Allergan, Amgen, ATI, Avanir, Dr. Reddy’s Laboratories Ltd., Kimberly-Clark, Scion NeuroStim, TEVA, and Pfizer Inc. Dr. Tepper has also received royalties or licensing fees from Springer and the University of Mississippi Press. He has disclosed a financial relationship with the American Headache Society, Dartmouth-Hitchcock Medical Center, and has stock options with ATI.

Planning Committee Disclosures

The individual listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, has no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at lisa@medicaled.com.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Teva Pharmaceuticals

©2017 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

Please Log In or Register to continue.